Ingrid Verhaart, PhD
Dr. Ingrid Verhaart was a postdoctoral researcher in the DMD Genetic Therapy Group since februari 2018.
She studied Biomedical Sciences at the Leiden University from 2004 to 2009. During her PhD at the department of Human Genetics of the Leiden University Medical Center (LUMC) under supervision of prof. dr. Gertjan van Ommen and dr. Annemieke Aartsma-Rus she worked on the pre-clinical optimization of antisense oligonucleotide (AON) mediated exon skipping for Duchenne muscular dystrophy (DMD). In May 2014 she defended her thesis titled: “Optimising antisense oligonucleotide-mediated exon skipping for Duchenne muscular dystrophy”. Thereafter she has worked at the Newcastle University on spinal muscular atrophy (SMA), DMD and muscular dystrophy type 1 (DM1).
In February 2018 she returned to the DMD genetic therapy group. She was involved in the validation lab, which aims to evaluate compounds that may be of benefit to Duchenne patients in preclinical DMD animal models. Next to her work in the validation lab, she also worked for the Duchenne Parent Project (DPP)/World Duchenne Organization (WDO). Ingrid has authored 18 articles, of which 13 as a first author, and a book chapter.